Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp has demonstrated strong financial performance, with its gross margin increasing by 240 basis points year-over-year and its operating margin rising by 390 basis points year-over-year, contributing to a projected FY25 operating margin of approximately 24%. The company's plasma revenue experienced growth attributed to premium pricing from technology upgrades, alongside share gains and increased collections, while the hospital segment, particularly the vascular closure business, also reported impressive growth rates in the mid-20s percentage range. Potential growth drivers include an acceleration in plasma collection volumes, further margin enhancements, and strategic acquisitions, reinforcing a positive outlook for its financial trajectory.

Haemonetics Corp has experienced a substantial slowdown in its revenue growth, with overall organic revenue declining to -0.3% in F3Q25, down from 3.7% in F2Q25, indicating potential operational challenges. The company has revised its growth expectations downward, particularly for the plasma and hospital segments, projecting organic growth rates of 12-14% for the hospital segment and a decline of 5-7% for the blood center segment in FY25. Furthermore, the bear case scenario suggests that revenue could slow to low-single digits, exacerbating concerns regarding operating margins and earnings that fall below consensus estimates, thus contributing to a negative outlook on the stock.